CynosureLutronic
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, CynosureLutronic sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
CynosureLutronic: 9 sponsored US clinical trials, 1 recruiting.
CynosureLutronic sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. The most-studied condition in this pipeline is Benign Pigmented Lesions, with 1 trials.
Top-decile sponsor footprint
CynosureLutronic ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth
NCT07588243
Pilot Evaluation of the Lutronic PicoPlus System for the Treatment of Benign Pigmented Lesions of the Hands
NCT04208100
LaseMD System for the Treatment of Melasma
NCT03456674
Safety and Efficacy Evaluation of the Xerf Device for Aesthetic Treatments
NCT07585591
Safety and Efficacy of Electronic Stimulation for Circumferential Reduction and Muscle Toning
NCT06152900
Lutronic Genius System for Neck Treatment
NCT03534609
Lutronic Infini and LaseMD Systems in Combination Treatment
NCT03409965
Lutronic LaseMD for Treatment of Benign Pigmented Lesions
NCT03409952
Lutronic PicoPlus Exploratory Clinical Trial
NCT03415685
Therapeutic Areas
What is open in the CynosureLutronic pipeline
1 recruiting of 9 indexed (11% open); 5 completed (56%).
Phase labels are sparse on this sponsor index, so phase mix is not charted here.
Top condition: Benign Pigmented Lesions (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
CynosureLutronic: open-pipeline peers nationwide
Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
CynosureLutronic sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this CynosureLutronic page
9 registered trials is a research-attention snapshot, not an endorsement of CynosureLutronic or any single study.
- 1 of CynosureLutronic's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Benign Pigmented Lesions is the condition CynosureLutronic studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Benign Pigmented Lesions trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
CynosureLutronic pipeline card: 9 registered trials from official public datasets.Report a data error.